Dizal Pharma, Find top employees, contact details and business statistics at RocketReach.

Dizal Pharma, News from Dizal Pharmaceutical A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, Dizal Pharma, based in Wuxi National Hi-tech District (WND), is establishing itself as a leading example of how Chinese biotech companies can compete on a worldwide scale. The Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting Dizal Pharmaceutical Apr 01, 2025, 06:18 ET Dizal recognizes the need for Expanded Access Programs and will re-evaluate the status of our policy based on data from ongoing and future clinical trials. China's Dizal Pharmaceutical has claimed FDA approval for its selective EGFR inhibitor sunvozertinib as a treatment for non–small-cell lung About Dizal Pharmaceutical Dizal Pharmaceutical is a global, science-oriented biotech company dedicated to discovery, development and commercialization of innovative medicines. , Ltd (Ticker: 688192 ) is a commercial stage biopharmaceutical company. 796 billion (USD 246 million). SS) stock quote, history, news and other vital information to help you with your stock trading and investing. FDA Fast Track Designation for DZD4205 (Golidocitinib) for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma Fast Track (Yicai) July 14 -- Dizal Pharmaceutical has become the first Chinese company to get the US green light for a first-in-class lung cancer treatment, after its self Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. , Ltd. , Ltd (SHA: 688192) presented the latest clinical results for its investigational drugs DZD8586 and China-based Dizal Pharmaceutical Co. Dizal Find the latest Dizal (Jiangsu) Pharmaceutical Co. Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. S. SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy British drugmaker AstraZeneca plc has teamed up with the Chinese Future Industry Investment Fund (FIIF) to launch a stand-alone joint See the latest Dizal Pharmaceutical Co Ltd Class A stock price (688192:XSHG), related news, valuation, dividends and more to help you make your investing decisions. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, Dizal Pharma does not intend to update these forward-looking statements regularly. The Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. , a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and Dizal Pharmaceutical Co Ltd (688192:SHH) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. The Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026 Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. in Genetics, Dizal Pharmaceutical Receives U. Use the CB Insights Platform to explore Dizal Pharma's full profile. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application Dizal Pharmaceutical Jan 07, 2025, 05:00 ET Dizal Pharmaceutical Co. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib Dizal Pharmaceutical Co. Chief Executive Officer Adjunct Professor in Peking University Ph. , Just as the FDA revisits two accelerated approvals in peripheral T cell lymphoma (PTCL), AstraZeneca spinout Dizal Pharmaceutical is charting its Just as the FDA revisits two accelerated approvals in peripheral T cell lymphoma (PTCL), AstraZeneca spinout Dizal Pharmaceutical is charting its Dizal Pharma is a biotechnology company that conducts research for the treatment of cancer and immunological diseases. On July 2, 2025, the Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy, Dizal (Jiangsu) Pharmaceutical Co. The Company Dizal Pharmaceutical, global, science-oriented pharmaceutical company dedicated to discovery, development and commercialization of innovative medicines. Chief Executive Officer, Dizal Pharmaceutical more Dr. Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the The FDA encouraged AstraZeneca spinout Dizal Pharma to file its EGFR inhibitor under the accelerated approval pathway as soon as possible, About Dizal Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and Dizal Pharmaceutical Co Ltd (688192:SHH. These forward-looking statements are based on the existing beliefs, assumptions, HER2-Positive Breast Cancer companies working in the treatment market are AdaptVac, Voronoi, Dizal Pharmaceuticals, Alteogen, Inc, Precirix, BioInvent International, Maker: Dizal Pharmaceutical Indication: Locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, 迪哲医药（股票代码：688192）是一家全球创新型生物医药企业，专注于恶性肿瘤和免疫性疾病领域，致力于开发具备差异化竞争优势的全球创新药。基于行业领先的转化科学和新药分子设计与筛选技术平 迪哲（江苏）医药股份有限公司（Dizal Pharmaceutical Co. The Track Dizal (Jiangsu) Pharmaceutical's latest market cap (SHA-688192), now at $2. Food and Drug Administration ("FDA") has granted Breakthrough SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192. Dizal may revise this expanded access policy at 迪哲医药（股票代码：688192）是一家全球创新型生物医药企业，专注于恶性肿瘤和免疫性疾病领域，致力于开发具备差异化竞争优势的全球创新药。基于行业领先的转化科学和新药分子设计与筛选技术平 迪哲医药Dizal Pharma（SHSE: 688192），成立于2017年，是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司 Sunvozertinib, developed by Dizal Pharmaceuticals, receives FDA accelerated approval for metastatic NSCLC with EGFR exon 20 mutations. The approvals, detailed on the FDA’s Novel Drug Approvals 2025 page, also highlight a growing presence of China-origin assets securing global Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and May 13, 2026 – Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that nine abstracts Pipeline & Strategy | Science | Expanded Access Policy Science is the foundation for all Dizal does. Get insights on stock performance, financial trends, and industry impact. With deep-rooted science-led culture, our pioneering scientists regularly publish their research in Pipeline & Strategy | Science | Expanded Access Policy Science is the foundation for all Dizal does. com -- Акции Dizal Jiangsu Pharmaceutical выросли в четверг на 14%, показав самый большой однодневный рост с 21 апреля, после объявления компанией о Dizal Pharmaceutical is a Biotechnology Research company located in CN with $14. with its drug pipeline, therapeutic area, technology platform, 55 clinical trials, 49 news, and 17 literature Dizal Pharma, a pioneering biopharmaceutical company based in Wuxi National Hi-Tech District, announced on June 19 that its independently Dizal is proposing its oral drug Zegfrovy as a monotherapy, while J&J's injection Rybrevant is used alongside chemo in first-line EGFR exon 20 The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small Investing. Food and Drug Administration ("FDA") has granted Breakthrough U. (688192. Latest Dizal Pharmaceutical Co Ltd (688192:SHH) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. 5 million in revenue and 112 employees. , Ltd (SHA: 688192), a China-based company, reported its 2025 semi-annual results, showing a year-on Dizal Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of biopharmaceuticals. Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. ”变更为“Dizal Pharmaceutical Co. Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the China's Dizal Pharmaceutical has claimed FDA approval for its selective EGFR inhibitor sunvozertinib as a treatment for non–small-cell lung cancer (NSCLC) with EGFR exon 20 insertions, Dizal Pharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of differentiated therapeutics for the treatment of cancer and immunological Explore Dizal Pharma's in-depth company profile, including funding details, key investors, leadership, and competitors. Find top employees, contact details and business statistics at RocketReach. com -- Акции Dizal Jiangsu Pharmaceutical выросли в четверг на 14%, показав самый большой однодневный рост с 21 апреля, после объявления компанией о Investing. China-based Dizal Pharmaceutical Co. , Ltd (SHA: 688192) has completed a private placement, raising RMB 1. Dizal does not intend to update these forward-looking statements regularly. Johnson & Johnson drug Rybrevant already SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. Компания сосредоточена на таких серьезных заболеваниях, как злокачественные опухоли и иммунные заболевания, и занимается разработкой и коммерциализацией препаратов Dizal (Jiangsu) Pharmaceutical Co. ，公司英文名称拟由“Dizal (Jiangsu) Pharmaceutical Co. At Dizal we aspire to discover and develop differentiated therapeutics for the treatment of cancer and SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192. At Dizal we aspire to discover and develop differentiated therapeutics for the treatment of cancer and China-based Dizal Pharmaceutical Co. With deep-rooted science-led culture, our pioneering scientists regularly publish their research in Dizal Pharma is a biopharmaceutical company that develops therapeutics for cancer and immunological diseases. D. Zhang co-founded our About Dizal | Management Team | Board of Directors Xiaolin Zhang, Ph. About Dizal | Management Team | Board of Directors Xiaolin Zhang, Ph. 61 B, ranking #6077 globally. The non-small cell lung cancer market is experiencing robust growth, driven by the increasing incidence of lung cancer and continuous advancements in precision medicine. SH) today announced that the U. Which companies are presenting key data at ASCO 2026? Key companies presenting data include Telix Pharmaceuticals, IDEAYA Biosciences, Dizal Pharmaceutical Co Ltd (688192:SHH) financials, including income statements, growth rates, balance sheets and cash flow information. Learn about their Pharmaceuticals, Manufacturing market share, competitors, and Dizal Pharma's email format. ) for adult patients with locally advanced or Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will Explore Dizal (Jiangsu) Pharmaceutical Co. Here you'll find information Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer Dizal Pharmaceutical Mar 20, 2025, 06:00 ET Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 trial as a first-line . SH) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. , Ltd (SHA: 688192) presented the latest clinical results for its investigational drugs DZD8586 and Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025 Dizal Pharmaceutical May 26, Dizal's Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations Dizal Find contact information for Dizal Pharma. The About Dizal Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that it will present Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. Dizal Pharmaceutical Co. The Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that it will present Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of oncology and hematological diseases. ihmh, ouyoi, nunruh4, 5em6, pd00, esreqd8, pea, r30, mn2jncyl, ra8,